Patents by Inventor Per Johan Lundberg
Per Johan Lundberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040234594Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: ApplicationFiled: October 23, 2003Publication date: November 25, 2004Inventors: Per Johan Lundberg, Kurt Lovgren
-
Publication number: 20030175352Abstract: A drug delivery system for oral administration in solid dry form of greasy/oily/sticky substance(s) and pharmaceutically active substance(s) or pharmaceutically active substance(s) which itself/themselves is/are greasy/oily/sticky) characterized by having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such solid, polymeric matrix beads comprising greasy/oily/sticky substances.Type: ApplicationFiled: March 11, 2003Publication date: September 18, 2003Inventors: Christer Karlsson, Per Johan Lundberg, Adam Rosinski, Malin Soderbom
-
Patent number: 6610323Abstract: An enteric coated pharmaceutical dosage form comprising an H+,K+-ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with instant release of the H+,K+-ATPase inhibitor. The portions are released in time by from 0.5 and up to 12 hours interval, preferably by from 0.5 and up to 8 hours, and more preferably by from 0.5 and up to 4 hours interval. The dosage form is intended for once daily administration.Type: GrantFiled: January 15, 1999Date of Patent: August 26, 2003Assignee: AstraZeneca ABInventors: Per Johan Lundberg, Brita Sjöblom
-
Patent number: 6605303Abstract: An enteric coated pharmaceutical extended release dosage form of a H+, K+-ATPase inhibitor giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile is obtained by a pharmaceutical composition which comprises a core material of a hydrophilic or hydrophobic matrix, and the H+, K+-ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form may be administered once daily.Type: GrantFiled: January 15, 2000Date of Patent: August 12, 2003Assignee: AstraZeneca ABInventors: Per-Gunnar Karehill, Per Johan Lundberg
-
Publication number: 20030113375Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: ApplicationFiled: September 4, 2002Publication date: June 19, 2003Applicant: AstraZeneca AB.Inventors: Per Johan Lundberg, Kurt Lovgren
-
Patent number: 6558703Abstract: A drug delivery system for oral administration in solid dry form of a greasy/oily/sticky substance and a pharmaceutically active substance or a pharmaceutically active substance which itself is greasy/oily/sticky characterized by having a plurality of porous inorganic particles of small size incorporated with considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such porous inorganic particles containing greasy/oily/sticky substances.Type: GrantFiled: January 4, 1999Date of Patent: May 6, 2003Assignee: AstraZeneca ABInventors: Christer Karlsson, Per Johan Lundberg, Adam Rosinski, Malin Söderbom
-
Patent number: 6555138Abstract: A drug delivery system for oral administration in solid dry form of greasy/oily/sticky substance(s) and pharmaceutically active substance(s) or pharmaceutically active substance(s) which itself/themselves is/are greasy/oily/sticky) characterized by having a plurality of solid, polymeric matrix beads comprising considerable amounts of greasy/oily/sticky substances and having fast release characteristics and a process for the preparation of such solid, polymeric matrix beads comprising greasy/oily/sticky substances.Type: GrantFiled: January 4, 1999Date of Patent: April 29, 2003Assignee: AstraZeneca ABInventors: Christer Karlsson, Per Johan Lundberg, Adam Rosinski, Malin Söderbom
-
Publication number: 20020086029Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: ApplicationFiled: December 18, 2001Publication date: July 4, 2002Applicant: AstraZeneca AB.Inventors: Per Johan Lundberg, Kurt Lovgren
-
Publication number: 20020012676Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: ApplicationFiled: October 6, 1999Publication date: January 31, 2002Inventors: PER JOHAN LUNDBERG, KURT LOVGREN
-
Patent number: 6284271Abstract: The present invention is related to an effervescent pharmaceutical preparation comprising effervescent excipients and a plurality of individual units comprising a pharmaceutically active compound and optional excipients wherein the units (1) are provided with a floating generating system. The floating generating systems comprises at least two coating layers, one of which is a gas generating layer (2) and the other layer is a barrier layer (3) enclosing the generated gas. Furthermore the invention is related to a process for the manufacture of the dosage forms, and their use in medicine.Type: GrantFiled: August 28, 1998Date of Patent: September 4, 2001Assignee: AstraZeneca ABInventors: Per Johan Lundberg, Mikael Thune
-
Patent number: 6132770Abstract: A new tableted multiple unit effervescent dosage form containing an acid susceptible proton pump inhibitor in the form of the racemate, an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, and effervescent tablet constituents. The proton pump inhibitor is preferably omeprazole or an alkaline salt thereof, or S-omeprazole or an alkaline salt thereof. Further the invention refers to a method for the manufacture of such a formulation, and the use of such a formulation in medicine.Type: GrantFiled: February 13, 1997Date of Patent: October 17, 2000Assignee: AstraZeneca ABInventor: Per Johan Lundberg
-
Patent number: 6086919Abstract: The invention is directed to a pharmaceutical composition which is a combination of the ACE inhibitor ramipril and a calcium antagonist of one of the dihydropyridine type compounds felodipine, nitrendipine, nifedipine and lacidipine. The pharmaceutical composition is for use in the therapy and treatment of hypertension.Type: GrantFiled: September 12, 1995Date of Patent: July 11, 2000Assignee: Astra AktiebolagInventors: Brigitte Bauer, Christer Karlsson, Per Johan Lundberg, Berit Nilsson, Anders Sandberg, Alfred Sickmuller
-
Patent number: 6013281Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.Type: GrantFiled: March 8, 1996Date of Patent: January 11, 2000Assignee: Astra AktiebolagInventors: Per Johan Lundberg, Kurt Lovgren